Antihistone antibodies in scleroderma

Aurora Parodi, M. Drosera, L. Barbieri, A. Rebora

Research output: Contribution to journalArticle

Abstract

Background: Antihistone antibodies (AHA) are usually considered the serological marker of drug-induced lupus erythematosus, but recently they have been found in patients with systemic scleroderma (SSc) and morphea. Objective and Methods: We determined AHA in 43 patients with SSc, 4 patients with overlap syndrome and 11 with morphea. Results and Conclusions: AHA were demonstrated in 41.8% of the SSc patients and in 36.3% of the morphea patients. Only 1 patient with overlap syndrome had AHA. Our SSc patients with AHA had frequent cardiac and renal involvements suggesting a prognostic value of AHA. In our morphea patients AHA did not correlate with clinical features.

Original languageEnglish
Pages (from-to)16-18
Number of pages3
JournalDermatology
Volume191
Issue number1
DOIs
Publication statusPublished - 1995

Fingerprint

Localized Scleroderma
Antibodies
Systemic Scleroderma
Kidney
Pharmaceutical Preparations

Keywords

  • Antihistone antibodies
  • Morphea
  • Scleroderma

ASJC Scopus subject areas

  • Dermatology

Cite this

Parodi, A., Drosera, M., Barbieri, L., & Rebora, A. (1995). Antihistone antibodies in scleroderma. Dermatology, 191(1), 16-18. https://doi.org/10.1159/000246474

Antihistone antibodies in scleroderma. / Parodi, Aurora; Drosera, M.; Barbieri, L.; Rebora, A.

In: Dermatology, Vol. 191, No. 1, 1995, p. 16-18.

Research output: Contribution to journalArticle

Parodi, A, Drosera, M, Barbieri, L & Rebora, A 1995, 'Antihistone antibodies in scleroderma', Dermatology, vol. 191, no. 1, pp. 16-18. https://doi.org/10.1159/000246474
Parodi, Aurora ; Drosera, M. ; Barbieri, L. ; Rebora, A. / Antihistone antibodies in scleroderma. In: Dermatology. 1995 ; Vol. 191, No. 1. pp. 16-18.
@article{6cec6209da2747478c5ff5dc1db19edb,
title = "Antihistone antibodies in scleroderma",
abstract = "Background: Antihistone antibodies (AHA) are usually considered the serological marker of drug-induced lupus erythematosus, but recently they have been found in patients with systemic scleroderma (SSc) and morphea. Objective and Methods: We determined AHA in 43 patients with SSc, 4 patients with overlap syndrome and 11 with morphea. Results and Conclusions: AHA were demonstrated in 41.8{\%} of the SSc patients and in 36.3{\%} of the morphea patients. Only 1 patient with overlap syndrome had AHA. Our SSc patients with AHA had frequent cardiac and renal involvements suggesting a prognostic value of AHA. In our morphea patients AHA did not correlate with clinical features.",
keywords = "Antihistone antibodies, Morphea, Scleroderma",
author = "Aurora Parodi and M. Drosera and L. Barbieri and A. Rebora",
year = "1995",
doi = "10.1159/000246474",
language = "English",
volume = "191",
pages = "16--18",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Antihistone antibodies in scleroderma

AU - Parodi, Aurora

AU - Drosera, M.

AU - Barbieri, L.

AU - Rebora, A.

PY - 1995

Y1 - 1995

N2 - Background: Antihistone antibodies (AHA) are usually considered the serological marker of drug-induced lupus erythematosus, but recently they have been found in patients with systemic scleroderma (SSc) and morphea. Objective and Methods: We determined AHA in 43 patients with SSc, 4 patients with overlap syndrome and 11 with morphea. Results and Conclusions: AHA were demonstrated in 41.8% of the SSc patients and in 36.3% of the morphea patients. Only 1 patient with overlap syndrome had AHA. Our SSc patients with AHA had frequent cardiac and renal involvements suggesting a prognostic value of AHA. In our morphea patients AHA did not correlate with clinical features.

AB - Background: Antihistone antibodies (AHA) are usually considered the serological marker of drug-induced lupus erythematosus, but recently they have been found in patients with systemic scleroderma (SSc) and morphea. Objective and Methods: We determined AHA in 43 patients with SSc, 4 patients with overlap syndrome and 11 with morphea. Results and Conclusions: AHA were demonstrated in 41.8% of the SSc patients and in 36.3% of the morphea patients. Only 1 patient with overlap syndrome had AHA. Our SSc patients with AHA had frequent cardiac and renal involvements suggesting a prognostic value of AHA. In our morphea patients AHA did not correlate with clinical features.

KW - Antihistone antibodies

KW - Morphea

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=0029038717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029038717&partnerID=8YFLogxK

U2 - 10.1159/000246474

DO - 10.1159/000246474

M3 - Article

C2 - 8589476

AN - SCOPUS:0029038717

VL - 191

SP - 16

EP - 18

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 1

ER -